Journey Medical Announces Phase 1 Clinical Trial Assessing Impact Of DFD-29 On Microbial Flora Of Healthy Adult Subjects achieved All Three Primary Objectives, Subjects Completed 16-Week Treatment With No Significant Safety Issues
Portfolio Pulse from Benzinga Newsdesk
Journey Medical announced that its Phase 1 clinical trial assessing the impact of DFD-29 on the microbial flora of healthy adult subjects achieved all three primary objectives. The subjects completed a 16-week treatment with no significant safety issues.
June 13, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Journey Medical's successful Phase 1 clinical trial of DFD-29 may positively impact Dermira Inc. (DERM) as the trial achieved all primary objectives without significant safety issues.
The successful completion of the Phase 1 clinical trial for DFD-29 indicates that the treatment is safe and effective, which may lead to further development and potential commercialization. This could positively impact Dermira Inc. (DERM) as the company may benefit from the success of Journey Medical's product.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80